Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

Stopped early · Phase 2

Conditions studied: Paroxysmal Nocturnal Hemoglobinuria (PNH)

In brief

The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.

Key facts

Study ID

NCT03225287

Run by

Ra Pharmaceuticals, Inc.

People needed

19

Starts

2017-07-17

Expected to finish

2021-10-26

Last updated by the study team

2023-09-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan (RA101495) PNH study
• Evidence of ongoing clinical benefit in the opinion of the Investigator

You may not qualify if…

• History of meningococcal disease
• Current systemic infection or suspicion of active bacterial infection

Where it is running

• Investigative Site 4 — Los Angeles, California, United States
• Investigative Site 19 — Dallas, Texas, United States
• Investigative Site 3 — Gosford, Australia
• Investigative Site 5 — Melbourne, Australia
• Investigative Site 10 — Toronto, Canada
• Investigative Site 14 — Helsinki, Finland
• Investigative Site 9 — Ulm, Germany
• Investigative Site 17 — Budapest, Hungary
• Investigative Site 13 — Christchurch, New Zealand
• Investigative Site 12 — Hamilton, New Zealand
• Investigative Site 6 — Leeds, United Kingdom
• Investigative Site 7 — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.